Torrent Pharmaceuticals Limited has scheduled comprehensive investor engagement activities for February 13, 2026, to review its quarterly financial performance and engage with stakeholders. The pharmaceutical company made this announcement through regulatory filings dated February 2, 2026, addressed to both BSE Limited and National Stock Exchange of India Limited.

Board Meeting and Earnings Call Schedule

The company has planned a dual approach for stakeholder communication on February 13, 2026. The board meeting will focus on approving financial results for the quarter and nine months ended December 31, 2025, along with consideration of interim dividend payment for financial year 2025-26. Following this, the company will conduct a teleconference with investors and analysts at 6:30 PM to discuss the financial performance.

Conference Call Access Information

Torrent Pharmaceuticals has provided comprehensive dial-in details for the investor conference call, ensuring global accessibility for stakeholders. The company has arranged universal dial-in numbers for domestic participants and extensive international toll-free access across multiple countries.

Global Participation Framework

The earnings call demonstrates Torrent Pharmaceuticals' commitment to international investor engagement with toll-free access across major markets. Countries covered include Argentina, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Sweden, Thailand, UK, and USA. This extensive coverage reflects the company's global investor base and commitment to transparent communication.

Regulatory Compliance and Documentation

The announcement was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring proper market disclosure protocols. The filing was digitally signed by Chintan M. Trivedi, Company Secretary, on February 2, 2026, demonstrating adherence to corporate governance standards and regulatory requirements for listed pharmaceutical companies.

Torrent Pharmaceuticals Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection at its Dahej manufacturing facility with zero observations, marking a significant regulatory milestone for the pharmaceutical company.

Inspection Details

The USFDA conducted a comprehensive inspection of the Dahej manufacturing facility over a five-day period. The inspection parameters and outcomes are detailed below:

Regulatory Compliance Achievement

The completion of the USFDA inspection with zero observations represents a clean regulatory outcome for Torrent Pharmaceuticals. Zero observations indicate that the inspection team found no deficiencies or areas of concern during their comprehensive review of the facility's manufacturing processes, quality systems, and compliance protocols.

This outcome demonstrates the company's adherence to stringent international manufacturing standards and regulatory requirements set by the USFDA for pharmaceutical facilities.

Stock Exchange Notification

Torrent Pharmaceuticals has formally notified both major Indian stock exchanges about this development in compliance with regulatory disclosure requirements:

• BSE Limited: Notification sent under Scrip Code 500420
• National Stock Exchange: Notification sent under Symbol TORNTPHARM
• Regulatory Framework: Disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The notification was signed by Chintan M. Trivedi, Company Secretary, and submitted on January 23, 2026.

Manufacturing Facility Significance

The Dahej facility represents an important manufacturing asset for Torrent Pharmaceuticals in its pharmaceutical operations. The successful completion of this USFDA inspection without any observations strengthens the facility's regulatory standing and validates the company's manufacturing capabilities for potential US market operations.

This regulatory clearance enhances the company's compliance track record and supports its pharmaceutical manufacturing operations under international quality standards.